Avalo Therapeutics, Inc. (AVTX) Stock Grade

About Avalo Therapeutics, Inc.'s fundamentals

Avalo Therapeutics is a biotechnology company with a market capitalization of $792.7 million that is not currently profitable, reporting a net loss in its latest annual statement. The company experienced a significant revenue decline of 86.6% year-over-year, indicating substantial contraction in its commercial operations. With a net margin of -132642.4%, the company is burning cash substantially relative to its revenue base, and it does not pay a dividend. These metrics reflect a financially stressed stage typical of development-phase biotech firms, where profitability depends on clinical trial outcomes and future product commercialization.